Department of Orthopaedic Surgery, Ehime University School of Medicine, Tohon city, Ehime, Japan.
Spinal Cord. 2010 Sep;48(9):685-90. doi: 10.1038/sc.2009.194. Epub 2010 Jan 12.
An in vivo study using a spinal cord compression model in rats.
To evaluate the effect of adenosine on thermal hyperalgesia after spinal cord injury (SCI).
After SCI, some patients suffer dysesthesia that is unresponsive to conventional treatments. We previously established a rat thoracic spinal cord mild-compression model by which we were able to induce thermal hyperalgesia in the hind limbs.
The thoracic spinal cord was compressed gently using a 20-g weight for 20 min. The withdrawal latency in response to thermal stimulation was monitored bilaterally in the hind limbs using Hargreaves' Plantar test apparatus.
SCI-induced thermal hyperalgesia was mimicked by the intrathecal application of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist. Hyperalgesia induced by SCI was significantly inhibited by the intrathecal application of 10-30 nmol chloro-adenosine (Cl-adenosine), a nonselective adenosine receptor agonist. The effect of Cl-adenosine (10 nmol) on hyperalgesia after SCI was blocked by the simultaneous application of DPCPX. Intrathecal application of R(-)N6-(2phenylisopropyl) adenosine (R-PIA; 10 nmol), a selective A1 receptor agonist, also inhibited SCI-induced hyperalgesia. In contrast, intrathecal application of CGS21680, a selective adenosine A2a receptor agonist, did not inhibit SCI-induced hyperalgesia.
These results suggest that adenosine inhibits hyperalgesia through the stimulation of A1 receptors. Adenosine or adenosine A1 receptor agonists should be considered as candidates for new therapeutic methods for treating post-SCI dysesthesia.
一项在大鼠脊髓压迫模型中进行的体内研究。
评估腺苷对脊髓损伤(SCI)后热痛觉过敏的影响。
SCI 后,一些患者会出现感觉异常,而常规治疗对此无效。我们之前建立了一个大鼠胸段脊髓轻度压迫模型,通过该模型我们能够诱导后肢热痛觉过敏。
使用 20g 的重量轻柔地压迫胸段脊髓 20 分钟。使用 Hargreaves 足底测试仪器在双侧后肢监测对热刺激的退缩潜伏期。
鞘内给予选择性腺苷 A1 受体拮抗剂 8-环戊基-1,3-二丙基黄嘌呤(DPCPX)可模拟 SCI 引起的热痛觉过敏。鞘内给予非选择性腺苷受体激动剂氯腺苷(Cl-adenosine,10-30nmol)可显著抑制 SCI 引起的痛觉过敏。Cl-adenosine(10nmol)对 SCI 后痛觉过敏的作用可被 DPCPX 同时给药所阻断。鞘内给予选择性 A1 受体激动剂 R(-)N6-(2-苯基异丙基)腺苷(R-PIA;10nmol)也抑制 SCI 引起的痛觉过敏。相比之下,鞘内给予选择性腺苷 A2a 受体激动剂 CGS21680 则不能抑制 SCI 引起的痛觉过敏。
这些结果表明,腺苷通过刺激 A1 受体抑制痛觉过敏。腺苷或腺苷 A1 受体激动剂可被视为治疗 SCI 后感觉异常的新治疗方法的候选药物。